| Wednesday, October 04, 2006 |
|
| Canadian regulators approved the drug Tysabri for the treatment of relapsing-remitting forms of multiple sclerosis. The drug is sold by U.S. company Biogen Idec (BIIB) and Ireland's Elan (ELN) . Biogen Idec was up $1.02, or 2.3%, at $45.90, and Elan was adding 14 cents, or 0.9%, to $15.70. |
posted by pharma-insight @ 1:53 PM  |
|
|
|
